Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.86−0.10 (-2.53%)
Close on Nov 17, 2026Market cap $188.72MP/E –Yield –
Artiva Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Artiva Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.86M, up 22.8% year over year. For fiscal 2025 it was $69.54M, up 38.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.54M | +38.2% |
| FY2024 | Dec 31, 2024 | $50.33M | +0.2% |
| FY2023 | Dec 31, 2023 | $50.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.93M | +22.8% |
| Q1 FY2026 | Mar 31, 2026 | $19.31M | +13.3% |
| Q4 FY2025 | Dec 31, 2025 | $16.99M | +27.6% |
| Q3 FY2025 | Sep 30, 2025 | $17.63M | +30.4% |
| Q2 FY2025 | Jun 30, 2025 | $17.86M | +44.8% |
| Q1 FY2025 | Mar 31, 2025 | $17.05M | +52.9% |
| Q4 FY2024 | Dec 31, 2024 | $13.32M | +19.4% |
| Q3 FY2024 | Sep 30, 2024 | $13.52M | +3.5% |
| Q2 FY2024 | Jun 30, 2024 | $12.33M | +9.5% |
| Q1 FY2024 | Mar 31, 2024 | $11.16M | – |
| Q4 FY2023 | Dec 31, 2023 | $11.15M | – |
| Q3 FY2023 | Sep 30, 2023 | $13.07M | – |
| Q2 FY2023 | Jun 30, 2023 | $11.26M | – |
See a number that looks wrong?